{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.8","upperLimit":"95.9","value":"92.9"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.8","upperLimit":"96.6","value":"93.8"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.7","upperLimit":"98.7","value":"96.9"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"}],"units":"Participants"}],"description":"The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and who underwent RP and PLND","id":"OG000","title":"Efficacy Analysis Population"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration","title":"Specificity","type":"PRIMARY","unitOfMeasure":"percentage"}